ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vaccine developer Dynavax Technologies has acquired Rhein Biotech, a maker of vaccines and biopharmaceuticals, from Crucell for about $12 million. Crucell obtained the firm as part of its recent acquisition of Berna Biotech. Rhein Biotech is headquartered in Düsseldorf, Germany, and employs about 45 people. Dynavax says the purchase provides it with a European Union-certified vaccine plant and control over the production of hepatitis B surface antigen.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X